A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies. Robert H. Vonderheide, MD, DPhil, director of the Abramson...
Original Article: Turning up the heat on resistant tumours with novel immunotherapies